| 摘要 |
The present invention pertains to a method for the production of recombinant CI esterase inhibitor (CI IA), said method comprising culturing in vitro, under serum-free conditions, a human host cell transfected with an exogenous nucleic acid sequence encoding said CI esterase inhibitor, wherein the human host cell is selected from the group consisting of an immortalized cell from the placenta, an immortalized cell from the amniotic to which the membrane, an immortalised cell from the amniotic fluid, HEK cell lines and a unique HEKts cell line, which works optimally with the vector system, developed by HumanCell Co. (HumanCell Co. Naperville, Illinois, U S A), CAP cell lines and CAP-T cell lines, also disclosed are a human host cell encoding the CI esterase inhibitor (CI IA), a recombinant CI esterase inhibitor (CI IA), a composition comprising the recombinant CI esterase inhibitor (CI IA), use of the recombinant CI esterase inhibitor (CI IA), an antibody raised against the recombinant CI esterase inhibitor (CI IA), a method for detecting and/or screening and/or monitoring cancer in an individual and a method of diagnosing rejection of transplants. |
